Annexon, Inc. Common Stock
Compare this stock
ANNX Stock Report Card
$
31%
Performance
Score:
10/100
ANNX returned -58.14% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Sentiment
Score:
72/100
ANNX had a bullish sentiment score of 71.85% across Twitter and StockTwits over the last 12 months. It had an average of 2.00 posts, 0.00 comments, and 0.07 likes per day.
Technicals
Score:
64/100
ANNX receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
Earnings
Score:
10/100
ANNX has missed earnings 7 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 19 quarters, ANNX has had 0 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
Score:
49/100
ANNX has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.
Annexon, Inc. Common Stock Summary
Nasdaq / ANNX
Healthcare
Biotechnology
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
ANNX scored poorly on our reportcard. Here are some similar companies and how they performed.
